Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck ’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients
Dateline City:
KENILWORTH, N.J. KEYNOTE-024, Published in The New England Journal of Medicine, Showed KEYTRUDA as Monotherapy Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with High Levels of PD-L1 Expression KEYNOTE-021, Cohort G, Published in The Lancet Oncology, Showed KEYTRUDA in Combination with Chemotherapy Demonstrated Superior Efficacy Compared to Chemotherapy Alone as First-Line Treatment; Trial Enrolled Patients Regardless of PD-L1 ExpressionKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from two major studies of KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, in the first-line
treatment of patients with metastatic non-small cell lung cancer (NSCLC)
at the ESMO 2016 Congress, the annual meeting of the European Society
for Medical Oncology:Language:
EnglishContact: Media:Pamela Eisele, 267-305-3558Kim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer ESMO Keytruda MSD NYSE:MRK Source Type: news
More News: Drugs & Pharmacology